THE ECONOMIC COSTS OF CORRECTION OF ADVERSE DRUG REACTIONS IN THERAPEUTIC PATIENTS

Download full text PDF
DOI: https://doi.org/10.29296/25419218-2019-04-07
Issue: 
4
Year: 
2019

1-I.M. Sechenov First Moscow State Medical University (Sechenov University), 8, Trubetskaya St., Build. 2, Moscow 119048, Russian Federation; 2-Clinical Trials and Healthcare Technology Assessment scientific-research Centre of Moscow Department of Healthcare, 12, Minskaya St., Build. 2, Moscow 121096, Russian Federation; 3-Medical Institute of Continuing Education, Moscow State University of Food Production, 11, Volokolamskoe Shosse, Moscow 125080, Russian Federation; 4-Research Institute for Clinical and Economic Expertise and Pharmacoeconomics, 21/6, Novomytishchinsky Prospect, Mytishchi, Moscow Region 141008, Russian Federation; 5-A.I. Evdokimov Moscow State University of Medicine and Dentistry, 20, Delegatskaya St., Build. 1, Moscow 127473, Russian Federation

Introduction. Adverse drug reactions (ADR) are one of the causes of disability and deaths worldwide, putting a substantial social and economic burden. Information about the nature of the costs makes it possible to reveal what causes the highest costs and to what one you should pay attention during investigations. Objective: to make an economic assessment of the costs of ADR correction in therapeutic patients. Material and methods. The 2014 to 2018 works estimating the cost of ADR correction in therapeutic patients, in whom the proportion of diseases was 47%, were sought in the eLibrary.ru database. Works on the following nosological entities: rheumatology, cardiology, pulmonology, neurology, endocrinology, nephrology, and gastroenterology were selected. Results. Among the analyzed nosological entities, «Rheumatology» (8 publications) held the lead in the number of studies; «Cardiology» (6 publications) was next, and «Pulmonology» (5 publications) ranked third. The maximum costs of correction within 1 year were in the «Nephrology» profile (293.7 thousand rubles), the minimum ones were in the «Gastroenterology» profile (15.5 thousand rubles). The total cost of ADR in the treatment of therapeutic diseases profile can amount to 1.1 million rubles per year. Conclusion. The costs of ADR correction considerably increase the direct expenditures on the management of therapeutic patients.
Keywords: 
adverse drug reaction
side effect
expenditures
clinical and economic study
References: 
  1. Lazarou J., Pomeranz B. H., Corey P. N. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. Jama, 279 (15), 1200–5. DOI: 10.1001/jama.279.15.1200
  2. World Health Organisation. Global Health Observatory (GHO) Data. Available at https://www.who.int/topics/global_burden_of_disease/ru/ [Accessed 07 December, 2018]
  3. Institute for Health Metrics and Evaluation (IHME). GBD Compare Data Visualization. Seattle, WA: IHME, University of Washington, 2018. Available at http://vizhub.healthdata.org/gbd-compare. [Accessed 07 December, 2018]
  4. Formica D. et al. The economic burden of preventable adverse drug reactions: a systematic review of observational studies. Expert opinion on drug safety. 2018; 17 (7): 681–95. https://doi.org/10.1080/14740338.2018.1491547
  5. Krysanova V.S., Krysanov I.S., Zhuravleva M.V., Gurevich K.G., Ermakova V.Yu. Economic evaluation of the adverse drug reactions costs during the therapy. Farmatsiya, 2018; 67 (8): 44–50 https://doi.org/10.29296/25419218-2018-08-08 (in Russian).
  6. Kulikov A.Yu., Pochuprina A.A. Pharmacoeconomic evaluation of abatacept versus adalimumab based on cost-effectiveness analysis in adult patients with rheumatoid arthritis. Farmakoekonomika: teoriya i praktika, 2015; 3 (3): 25–30 (in Russian).
  7. Kolbin A.S., Kurylev A.A., Proskurin M.A., Balykina Y.E. Health economic assessment of antirheumatic drugs in patients with reumathoid arthritis progressed after metotrexate. Farmakoekonomika. Sovremennaya farmakoekonomika i farmakoepidemiologiya, 2016; 9 (3): 20–8. https://doi.org/10.17749/2070-4909.2016.9.3.020-028 (in Russian).
  8. Zyryanov S.K., Cheberda A.E., Belousov D.Y. Pharmacoeconomic analysis of subdermal tocilizumab in patients with rheumatoid arthritis. Kachestvennaya klinicheskaya praktika, 2015; 4: 33–41 (in Russian).
  9. Zyryanov S.K., Cheberda A.E., Belousov D.Y. Pharmacoeconomic analysis of Actemra® in first-line treatment of rheumatoid arthritis in the modes of combination and monotherapy. Kachestvennaya klinicheskaya praktika, 2016; 3: 22–34 (in Russian).
  10. Tsvetkova E.S., Belousov D.Y., Afanasyeva E.V. Pharmacoeconomic analysis of Movalis in patients with osteoarthritis and rheumatoid arthritis. Kachestvennaya klinicheskaya praktika, 2015; 1: 66–76 (in Russian).
  11. Makarova E.I., Tolordava G.A., Arinina E.E. Pharmacoeconomic analysis of Thrombo ASS in treatment of patients with previous cardiovascular events. Farmakoekonomika: teoriya i praktika, 2015; 3 (4): 69–74 https://doi.org/10.30809/phe.4.2015.1 (in Russian).
  12. Kulikov A.Yu. Pharmacoeconomic analysis of dual antiplatelet therapy with acetylsalicylic acid and ticagrelor in patients with acute coronary syndrome receiving treatment using percutaneous coronary vascularization. Farmakoekonomika: teoriya i praktika, 2016; 4 (1): 23–7 (in Russian).
  13. Belousov D.Y., Afanasyeva E.V. Cost-minimization analysis of application acetylsalicylic acid in cardiac elderly patients. Kachestvennaya klinicheskaya praktika, 2015; 1: 3–8 (in Russian).
  14. Kolbin A.S., Vilyum I.A., Proscurin M.A., Balikina Yu.Ye. Pharmacoeconomic analysis of telavancin use in russian healthcare system for treatment of patients with nosocomial pneumonia. Farmakoekonomika: teoriya i praktika, 2016; 4 (2): 88–92 (in Russian).
  15. Kulikov A.Yu., Makarova E.I. Pharmacoeconomic analysis of Foster® use in the treatment of bronchial asthma. Farmakoekonomika: teoriya i praktika, 2017; 5 (3): 54–8 (in Russian).
  16. Kulikov A.Yu., Makarova E.I. Pharmacoeconomic analysis of continuation of use of Symbicort® turbuhaler® as the sole inhaler for bronchial asthma therapy. Farmakoekonomika: teoriya i praktika, 2017; 5 (3): 34–43 (in Russian).
  17. Kosolapov E.G., Kochenkov F.S., Pogudina N.L. et al. Cost-minimization of vilanterol/umeclidinium versus olodaterol/tiotropium in the basic therapy of severe and very severe COPD. Farmakoekonomika. Sovremennaya farmakoekonomika i farmakoepidemiologiya, 2017; 10 (2): 22–30. https://doi.org/10.17749/2070-4909.2017.10.2.022-030 (in Russian).
  18. Kosolapov E.G., Kochenkov F.S., Pogudina N.L., Blinov D.V. Cost-effectiveness of vilanerol/umeclidinium versus tiotropium in severe and very severe COPD. Farmakoekonomika. Sovremennaya farmakoekonomika i farmakoepidemiologiya, 2017; 10 (2): 31–40. https://doi.org/10.17749/2070-4909.2017.10.2.031-040 (in Russian).
  19. Ugrekhelidze D.T., Kulikov A.Yu. Pharmacoeconomic analysis of different types of treatment for spastic forms of cerebral palsy. Farmakoekonomika: teoriya i praktika, 2015; 3 (3): 62–9. https://doi.org/10.30809/phe.3.2015.5 (in Russian).
  20. Kulikov A.Yu., Ugrekhelidze D.T. Pharmacoeconomic study of botulinum toxin type a in treatment of post-stroke spasticity in the upper limb. Farmakoekonomika: teoriya i praktika, 2014; 2 (3): 28–37 (in Russian).
  21. Makarova E.I., Kulikov A.Yu. Pharmacoeconomics analysis of the medicinal product Copaxone-40 in treating multiple sclerosis. Farmakoekonomika: teoriya i praktika, 2016; 4 (3): 30–4 (in Russian).
  22. Belousov D.Y., Afanasyeva E.V. Pharmacoeconomic evaluation of pramipexole extended release monotherapy in early Parkinson’s disease. Kachestvennaya klinicheskaya praktika, 2015; 1: 53–64 (in Russian).
  23. Kulikov A.Yu., Novikov I.V. Pharmacoeconomic analysis of insulin degludec (Tresiba ®) use in basal therapy of type 2 diabetes. Farmakoekonomika: teoriya i praktika, 2014; 2 (1): 29–31. https://doi.org/10.30809/phe.1.2014.11 (in Russian).
  24. Kulikov A.Yu., Novikov I.V., Tolkushin A.G., Arinina E.E. Pharmacoeconomic evaluation of Sitagliptin compared to sulfonylruea derivatives in patients with type 2 diabetes not controlled by metformin monotherapy. Farmakoekonomika: teoriya i praktika, 2014; 2 (3): 47–50. https://doi.org/10.30809/phe.3.2014.5 (in Russian).
  25. Ionova T.I., Nikitina T.P., Rodionov A.Y., Kurbatova K.A. Pharmacoeconomic analysis of use the oral hypoglycemic agents in patients with type 2 diabetes mellitus according to a real clinical practice. Kachestvennaya klinicheskaya praktika, 2016; 1: 41–6 (in Russian).
  26. Yagudina R.I., Serpik V.G., Abdrashitova G.T. Pharmacoeconomic analysis of medical care for chronic renal disease patients in need of renal replacement therapy via peritoneal dialysis and hemodialysis in the Russian healthcare environment. Farmakoekonomika: teoriya i praktika, 2015; 3 (3): 103–10 (in Russian).
  27. Yagudina R.I., Serpik V.G., Abdrashitova G.T., Kotenko O.N. The economic burden of chronic kidney disease in the Russian Federation. Farmakoekonomika: teoriya i praktika, 2014; 2 (4): 34–9 (in Russian).
  28. Pyadushkina E.A. Clinical and economic analysis of the use of Vedolizumab in adult patients with ulcerative colitis. Meditsinskiye tekhnologii. Otsenka i vybor, 2016; 4: 64–78 (in Russian).
  29. Protcenko M.V., Pochuprina A.A. Estimating the costs of side effects in patients with hypertension taking ingibotory ACE. Sovremennaya organizatsiya lekarstvennogo obespecheniya, 2014; 4: 26–33 (in Russian).
  30. Anosov I.S., Loskutova E.E., Gushina Y.S. Pharmacoeconomic costs analysis of pharmacotherapy modifications due to adverse drug reactions. Sovremennyye problemy nauki i obrazovaniya, 2015; 2 (2): 799 (in Russian).